Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Caligan Partners LP reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 69.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 322,453 shares of the biotechnology company's stock after selling 720,436 shares during the quarter. Enanta Pharmaceuticals comprises about 1.1% of Caligan Partners LP's investment portfolio, making the stock its 11th biggest position. Caligan Partners LP owned 1.52% of Enanta Pharmaceuticals worth $3,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ENTA. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $35,000. US Bancorp DE increased its position in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at $122,000. Quest Partners LLC raised its stake in shares of Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $150,000 after acquiring an additional 9,692 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth about $191,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Down 2.6 %

NASDAQ:ENTA traded down $0.23 during midday trading on Friday, hitting $8.60. The stock had a trading volume of 225,002 shares, compared to its average volume of 186,321. Enanta Pharmaceuticals, Inc. has a one year low of $8.00 and a one year high of $17.80. The company has a market capitalization of $182.23 million, a price-to-earnings ratio of -1.57 and a beta of 0.56. The stock has a 50-day moving average of $10.81 and a 200 day moving average of $12.23.

Analysts Set New Price Targets

Several brokerages recently commented on ENTA. JMP Securities reiterated a "market outperform" rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Evercore ISI raised Enanta Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, August 6th. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a research note on Tuesday, August 6th. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, Robert W. Baird reduced their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.